Changes and significance of serum soluble programmed death-1 in patients with chronic hepatitis C
10.3760/cma.j.issn.0254-5101.2019.12.005
- VernacularTitle: 可溶性程序性死亡因子-1在慢性丙型肝炎患者血清中的变化及意义
- Author:
Xiaohui HUANG
1
,
2
;
Liang ZHOU
3
;
Lin GU
4
;
Xiaoyan LI
3
;
Yuehua HUANG
4
,
5
Author Information
1. Clinical Medicine Research Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
2. Guangdong Key Laboratory of Liver Disease Research, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
3. Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
4. Guangdong Key Laboratory of Liver Disease Research, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
5. Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
- Publication Type:Journal Article
- Keywords:
Soluble programmed death-1;
Chronic hepatitis C;
Liver fibrosis
- From:Chinese Journal of Microbiology and Immunology
2019;39(12):911-915
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the changes and significance of serum soluble programmed death-1 (sPD-1) in patients with chronic hepatitis C (CHC) and study its role in the progression of CHC.
Methods:Serum levels of sPD-1 in CHC patients and healthy controls (HC) were measured using ELISA and compared. Correlations of serum sPD-1 with peripheral hepatitis C virus (HCV) RNA, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and liver fibrosis (indicated by APRI) were analyzed.
Results:The serum sPD-1 level in the CHC group was significantly higher than that in the HC group (P<0.05), and positively correlated with peripheral HCV RNA, ALT and AST (P<0.05). In addition, the serum sPD-1 levels in patients with APRI greater than 1.2 (indicating severe liver fibrosis) were higher than those in patients without or with mild liver fibrosis (P<0.05).
Conclusions:sPD-1 might be involve in the progression of CHC. Measuring serum sPD-1 in CHC patients would assist the prediction of disease progression and help to make the correct diagnosis and appropriate clinical therapy decision.
